Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
about
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy aloneNovel homobarringtonie-containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy.Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome.
P2860
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Efficacy and toxicity of decit ...... ndrome: a retrospective study.
@en
type
label
Efficacy and toxicity of decit ...... ndrome: a retrospective study.
@en
prefLabel
Efficacy and toxicity of decit ...... ndrome: a retrospective study.
@en
P2093
P2860
P1433
P1476
Efficacy and toxicity of decit ...... yndrome: a retrospective study
@en
P2093
Lingyun Wu
Youshan Zhao
P2860
P304
P356
10.3109/10428194.2015.1096351
P577
2015-11-16T00:00:00Z